-
Pogacar expects Vingegaard Tour de France battle to last 'years'
-
Japan deploys bear cameras in mountains as attacks surge
-
New York ready for epic Swift-Kelce love story wedding
-
Djokovic has history in his sights at Wimbledon
-
Wildfires rage in southern France, 3,000 people evacuated
-
Ovechkin returning to Caps for 22nd NHL season
-
Hamilton gives F1 a piece of his mind over Lego cars
-
Faster than Mbappe: Australia flyer Bos races into World Cup conversation
-
Hong Kong bookseller once held in China dies in Taiwan
-
Trump wants 'senseless killing' in Ukraine to end: US official
-
Venezuelan rescue brings hope to nation in mourning
-
Eala writes history for Philippines in 'electric' Wimbledon atmosphere
-
Macabre night in La Guaira, Venezuela's earthquake epicenter
-
Wolff urges 'perspective' as Russell chases Mercedes' teammate Antonelli
-
Tesla global auto sales jump 25% in 2nd quarter, beating expectations
-
Superb Swiatek, Zverev cruise into Wimbledon last 32
-
Zverev routs Royer to reach Wimbledon third round
-
Ukraine, Russia vow escalation after Moscow attack kills 21 in Kyiv
-
Hot spell roasts eastern US ahead of holiday weekend
-
Slowing US job growth poses midterms challenge for Trump
-
Hamilton cools fans Ferrari fervour
-
Klopp poised to replace Nagelsmann as Germany coach: reports
-
Venezuela's diaspora searches for quake victims on social media
-
More than 400 dead in DR Congo's spreading Ebola outbreak
-
Albanian clashes as protest over Trump-linked resort boils over
-
Hot spell roasts eastern US as holiday weekend approaches
-
Desire key to Pogacar dominance, says former Tour king Froome
-
Superb Swiatek storms into Wimbledon last 32, Zverev waits
-
Rescuers dig out Venezuelan man eight days after quakes
-
Russian strikes kill 21 in biggest ever attack on Kyiv, mayor says
-
Anderson closes in on record Man City move
-
Swiatek sees off Pliskova to race into Wimbledon third round
-
England change five for South Africa Test
-
Dollar down, stocks shine after disappointing US jobs data
-
Lock Alemanno to make 100th Pumas appearance against Scotland
-
US job growth slows, posing questions for Trump before midterms
-
US posts weaker-than-expected job growth in June
-
Chanel eyes menswear with Charvet shirtmaker takeover
-
UK PM says 'deeply sorry' for decades of forced adoptions
-
Chanel eyes menswear with Charvet shirtmaker takevoer
-
Almost 1.2 mn apply for Spain's migrant regularisation
-
'I grabbed my child': Kyiv residents face devastation of biggest Russian barrage of war
-
Ukrainian state ordered Nord Stream sabotage: German prosecutors
-
Former top jockey Dettori breaks ribs in car crash
-
Swiatek, Zverev aiming to lay down Wimbledon markers
-
Rees-Zammit returns to wing as Wales face Fiji
-
German ruling coalition agrees on major reform package
-
Renovations on historic Paris Opera house extended by three years
-
European stocks climb after Asia rout
-
Thailand denies viral claim Macron knelt before king
China approves first domestic mRNA vaccine for Covid-19
China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.
The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for "emergency use" by Beijing's health regulator, the company said in a statement.
It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.
mRNA vaccines are considered among the most effective in reducing severe infections and deaths.
While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body's cells how to produce a protein -- in this case, the spike protein on the coronavirus that causes Covid.
The body's immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.
Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.
Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.
Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunisation gap.
J.Fankhauser--BTB